Seth Klarman portfolio · Q4 2013
The Baupost Group, L.L.C. · CIK 0001061768 ·13F filings on SEC EDGAR
In Q4 2013, The Baupost Group, L.L.C. reported 19 positions worth $3.5B. Its largest holding was MU at 31.8% of the portfolio, and the top 10 made up 95%. Its largest new position was 31620R105 ($64.1M), and it sold out of ORCL.
- NEW 3
- ADD 6
- REDUCE 3
- EXIT 4
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter.
Portfolio history
Q2 2013 to Q4 2013, 3 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
MU MICRON TECHNOLOGY INC | 31.83% | $15.43* | $1,065.11 | +6,801.3% | $55B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
88338T104 THERAVANCE INC | 20.35% | $38.53* | $10.54 | -72.6% | $212.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VSAT VIASAT INC | 19.76% | $71.36* | $70.38 | -1.4% | $783.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BP BP PLC-SPONS ADR | 7.80% | $41.82* | $43.99 | +5.2% | $249.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDIX IDENIX PHARMACEUTICALS LLC | 6.25% | $4.20* | $23.81 | +466.9% | $878.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
C.WS.A CITIGROUP INC-CW19 | 1.92% | $0.77* | $0.15 | -80.3% | $15.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
31620R105 FIDELITY NATIONAL FINANCIAL | 1.82% | $32.45 | $32.45 | 0.0% | $64.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
G2110R114 CHIPMOS TECH BERMUDA LTD | 1.79% | $19.13* | $19.80 | +3.5% | $65M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PBF PBF ENERGY INC-CLASS A | 1.76% | $27.11 | $76.96 | +183.9% | $152.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NG NOVAGOLD RESOURCES INC | 1.56% | $2.11* | $6.50 | +208.1% | $141M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELOS SYNERON MEDICAL LTD | 1.39% | $8.70* | $10.95 | +25.9% | $43.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROVI ROVI CORP | 1.21% | $22.84* | $19.48 | -14.7% | $42.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KIN KINDRED BIOSCIENCES INC | 0.92% | $11.17 | $9.17 | -17.9% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
018772103 ALLIANCE ONE INTL INC | 0.55% | $3.80* | $1.10 | -71.1% | $7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AIG.WS AMERICAN INTERNATIONAL-CW21 | 0.38% | — | $0.16 | — | $105K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
66988K102 NOVACOPPER INC | 0.22% | $1.75* | $0.50 | -71.4% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
053588109 AVEO PHARMACEUTICALS INC | 0.20% | $2.50* | $2.26 | -9.6% | $8.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALDW ALON USA PARTNERS LP | 0.16% | $16.66 | $23.31 | +39.9% | $7.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
293904108 ENZON PHARMACEUTICALS INC | 0.14% | $2.00* | $0.47 | -76.5% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Jun 30, 2013, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Sep 30, 2013, for the 16 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Sep 30, 2013 and not reported for Q4 2013.
SEC filings for Q4 2013
- 13F-HR 0001140361-14-006972 · accepted Feb 13, 2014, 21:08 UTC